Disability

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging...

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled...

First of its kind study into digital self-management support for autistic adults reveals significant improvements in anxiety levels and quality of life

Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced...

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting

Data were presented to demonstrate that DPM-1003 provides a mechanism-based approach to the treatment of Rett Syndrome and is poised...

Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients

MINNEAPOLIS, June 15, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...

error: Content is protected !!